beigene
IR Menu

Press Releases

Nov 13, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | RegularNews    read more...
Nov 07, 2018
BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | RegularNews    read more...
Nov 07, 2018
BeiGene Reports Third Quarter 2018 Financial Results | RegularNews    read more...
Nov 05, 2018
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology | RegularNews    read more...
Nov 01, 2018
BeiGene to Present Clinical Data on Tislelizumab and Zanubrutinib at the 60th American Society of Hematology Annual Meeting | RegularNews    read more...
Oct 24, 2018
BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | RegularNews    read more...
Oct 22, 2018
BeiGene Presents Preliminary Clinical Data on PARP Inhibitor Pamiparib in Combination with Low-Dose Temozolomide in Patients with Solid Tumors at European Society for Medical Oncology (ESMO) 2018 Congress | RegularNews    read more...
Oct 12, 2018
BeiGene Announces Updated Results from Phase 1 Clinical Trial of Zanubrutinib in Patients with Waldenström’s Macroglobulinemia | RegularNews    read more...
Oct 12, 2018
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies    read more...
Oct 10, 2018
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China | RegularNews    read more...
Oct 08, 2018
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings | RegularNews    read more...
Oct 01, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | RegularNews    read more...
Sep 25, 2018
BeiGene to Present at Upcoming Investor Conferences | RegularNews    read more...
Sep 21, 2018
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology | RegularNews    read more...
Sep 20, 2018
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology | RegularNews    read more...
Sep 20, 2018
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology | RegularNews    read more...
Sep 16, 2018
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology | RegularNews    read more...
Sep 07, 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors    read more...
Sep 05, 2018
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto | RegularNews    read more...
Sep 04, 2018
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | RegularNews    read more...